PFKFB2 Inhibits Ferroptosis in Myocardial Ischemia/Reperfusion Injury Through Adenosine Monophosphate-Activated Protein Kinase Activation

J Cardiovasc Pharmacol. 2023 Aug 1;82(2):128-137. doi: 10.1097/FJC.0000000000001437.

Abstract

Six-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 2 (PFKFB2) is a key regulator of glycolytic enzyme. This study identified whether PFKFB2 can regulate myocardial ferroptosis in ischemia/reperfusion (I/R) injury. Mice myocardial (I/R) injury and H9c2 cells oxygen-glucose deprivation/reperfusion (OGD/R) models were established. PFKFB2 expression was enhanced in I/R mice and OGD/R H9c2 cells. Overexpression of PFKFB2 improves heart function in I/R mice. Overexpression of PFKFB2 inhibits I/R and OGD/R-induced ferroptosis in mice and H9c2 cells. Mechanistically, overexpression of PFKFB2 activates the adenosine monophosphate-activated protein kinase (AMPK). AMPK inhibitor compound C reverses effect of PFKFB2 overexpression in reducing ferroptosis under OGD/R treatment. In conclusion, PFKFB2 protects hearts against I/R-induced ferroptosis through activation of the AMPK signaling pathway.

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Adenosine Monophosphate / pharmacology
  • Animals
  • Apoptosis
  • Ferroptosis*
  • Glucose / metabolism
  • Mice
  • Myocardial Reperfusion Injury* / metabolism
  • Reperfusion Injury* / metabolism
  • Signal Transduction

Substances

  • Adenosine Monophosphate
  • AMP-Activated Protein Kinases
  • Glucose